China Universal Asset Management Company’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

China Universal Asset Management Company’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,225	Closed	-$5.3K	–	488
2023 Q3	$5.3K	Buy	2,225 +1,088	+96%	+$2.28K	﹤0.01%	386
2023 Q2	$2K	Sell	1,137 -27	-2%	-$69	﹤0.01%	426
2023 Q1	$3.58K	Buy	1,164 +290	+33%	+$1.74K	﹤0.01%	401
2022 Q4	$4.63K	Buy	874 +70	+9%	+$320	﹤0.01%	308
2022 Q3	$3K	Buy	+804	New	+$2.66K	﹤0.01%	339

Other funds holding PSTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

China Universal Asset Management Company's PSTX Position: Q4 2023 in Review

China Universal Asset Management Company sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2023, closing a stake of 2,225 shares — an estimated $5.3K sold.

China Universal Asset Management Company first reported a position in PSTX in Q3 2022 and held it in 5 quarters. The position peaked at $5.3K in Q3 2023. 91 funds tracked by Wall St. Rank hold PSTX as of Q4 2023.

China Universal Asset Management Company reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
China Universal Asset Management Company sold 2,225 Poseida Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $5.3K.
China Universal Asset Management Company first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2022 and held it in 5 quarters.
China Universal Asset Management Company's Poseida Therapeutics, Inc. Common Stock position peaked at $5.3K in Q3 2023.
91 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2023.

Based on China Universal Asset Management Company's 13F filing for Q4 2023, filed 24 Jan 2024.